Characterization of sarcomas by means of gene expression

Journal of Laboratory and Clinical Medicine

Volumn 144, Issue 2, 2004, Pages 78-91

  Skubitz, Keith M ^a,b,c   Skubitz, Amy P N ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

Author keywords

cDNA; complementary DNA; complementary RNA; cRNA; dermatofibrosarcoma protuberans; DFSP; EST; expressed sequence tag; gastrointestinal stromal tumor; GIST; malignant fibrous histiocytoma; messenger RNA; MFH; mRNA; natural killer; NK; NOS

Indexed keywords

NITRIC OXIDE SYNTHASE;

ADOLESCENT; ADULT; AGED; ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; HISTOLOGY; HUMAN; LEIOMYOSARCOMA; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; MESENCHYMOMA; NEURILEMOMA; PRESCHOOL CHILD; SARCOMA; SYNOVIAL SARCOMA;

ADULT; AGED; BRAIN NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIPOSARCOMA; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; NEURILEMMOMA; RNA, NEOPLASM; SARCOMA;

EID: 4344713343     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lab.2004.04.005     Document Type: Article

References (36)

1. Kempson R.L., Kyriakos M. Fibroxanthosarcoma of the soft tissues A type of malignant fibrous histiocytoma. Cancer. 29:1972;961-976
2. Rooser B., Willen H., Gustafson P., Alvegard T.A., Rydholm A. Malignant fibrous histiocytoma of soft tissue A population-based epidemiologic and prognostic study of 137 patients. Cancer. 67:1991;499-505
3. Le Doussal V., Coindre J.M., Leroux A., Hacene K., Terrier P., Bui N.B., et al. Prognostic factors for patients with localized primary malignant fibrous histiocytoma A multicenter study of 216 patients with multivariate analysis. Cancer. 77:1996;1823-1830
4. Pezzi C.M., Rawlings M.S. Jr, Esgro J.J., Pollock R.E., Romsdahl M.M. Prognostic factors in 227 patients with malignant fibrous histiocytoma. Cancer. 69:1992;2098-2103
5. Weiss S.W., Enzinger F.M. Malignant fibrous histiocytoma An analysis of 200 cases. Cancer. 41:1978;2250-2266
6. Weiss S.W. Malignant fibrous histiocytoma. A reaffirmation. Am J Surg Pathol. 6:1982;773-784
7. Fletcher C.D., Gustafson P., Rydholm A., Willen H., Akerman M. Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas Prognostic relevance of subclassification. J Clin Oncol. 19:2001;3045-3050
8. Fletcher C.D. Pleomorphic malignant fibrous histiocytoma Fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. Am J Surg Pathol. 16:1992;213-228
9. Fletcher C.D. Malignant fibrous histiocytoma? Histopathology. 11:1987;433-437
10. Dehner L.P. Malignant fibrous histiocytoma. Nonspecific morphologic pattern, specific pathologic entity, or both? Arch Pathol Lab Med. 112:1988;236-237
11. Hedenfalk I., Duggan D., Chen Y., Radmacher M., Bittner M., Simon R., et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med. 344:2001;539-548
12. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., et al. Molecular portraits of human breast tumours. Nature. 406:2000;747-752
13. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 403:2000;503-511
14. Khan J., Wei J.S., Ringner M., Saal L.H., Ladanyi M., Westermann F., et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med. 7:2001;673-679
15. Hollowood K., Fletcher C.D. Malignant fibrous histiocytoma Morphologic pattern or pathologic entity? Semin Diagn Pathol. 12:1995;210-220
16. Skubitz K.M., Skubitz A.P. Differential gene expression in uterine leiomyoma. J Lab Clin Med. 141:2003;297-308
17. Skubitz K.M., Skubitz A.P. Differential gene expression in leiomyosarcoma. Cancer. 98:2003;1029-1038
18. Skubitz K.M., Skubitz A.P. Differential gene expression in renal-cell cancer. J Lab Clin Med. 140:2002;52-64
19. Nielsen T.O., West R.B., Linn S.C., Alter O., Knowling M.A., O'Connell J.X., et al. Molecular characterisation of soft tissue tumours A gene expression study. Lancet. 359:2002;1301-1307
20. Segal N.H., Pavlidis P., Antonescu C.R., Maki R.G., Noble W.S., DeSantis D., et al. Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Am J Pathol. 163:2003;691-700
21. Online Mendelian inheritance in man, OMIM, vol 2003. In: McKusick V, ed. Baltimore and Bethesda, Md: McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University and the National Center for Biotechnology Information, National Library of Medicine; 2000
22. Skytting B., Nilsson G., Brodin B., Xie Y., Lundeberg J., Uhlen M., et al. A novel fusion gene, SYT-SSX4, in synovial sarcoma. J Natl Cancer Inst. 91:1999;974-975
23. Crew A.J., Clark J., Fisher C., Gill S., Grimer R., Chand A., et al. Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. EMBO J. 14:1995;2333-2340
24. Clark J., Rocques P.J., Crew A.J., Gill S., Shipley J., Chan A.M., et al. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet. 7:1994;502-508
25. Skubitz KM, Cheng E, Clohisy D, Thompson R, Manivel C, Skubitz APN. Gene expression in lipoma, liposarcoma, and adipose tissue. Cancer Invest; in press
26. Skubitz KM, Skubitz APN. Gene expression in aggressive fibromatosis. J Lab Clin Med 2004;143:89-98
27. Allander S.V., Illei P.B., Chen Y., Antonescu C.R., Bittner M., Ladanyi M., et al. Expression profiling of synovial sarcoma by cDNA microarrays Association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. Am J Pathol. 161:2002;1587-1595
28. Demetri G.D. Identification and treatment of chemoresistant inoperable or metastatic GIST Experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). Eur J Cancer. 38:(suppl 5):2002;S52-59
29. Demetri G.D. Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development. Hematol Oncol Clin North Am. 16:2002;1115-1124
30. Rubin B.P., Singer S., Tsao C., Duensing A., Lux M.L., Ruiz R., et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 61:2001;8118-8121
31. Cosman D., Mullberg J., Sutherland C.L., Chin W., Armitage R., Fanslow W., et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 14:2001;123-133
32. Sutherland C.L., Chalupny N.J., Schooley K., VandenBos T., Kubin M., Cosman D. UL16 binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. J Immunol. 168:2002;671-679
33. Lee Y.F., John M., Edwards S., Clark J., Flohr P., Maillard K., et al. Molecular classification of synovial sarcomas, leiomyosarcomas and malignant fibrous histiocytomas by gene expression profiling. Br J Cancer. 88:2003;510-515
34. Nagayama S., Katagiri T., Tsunoda T., Hosaka T., Nakashima Y., Araki N., et al. Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray. Cancer Res. 62:2002;5859-5866
35. Allander S.V., Nupponen N.N., Ringner M., Hostetter G., Maher G.W., Goldberger N., et al. Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile. Cancer Res. 61:2001;8624-8628
36. Fritz B., Schubert F., Wrobel G., Schwaenen C., Wessendorf S., Nessling M., et al. Microarray-based copy number and expression profiling in dedifferentiated and pleomorphic liposarcoma. Cancer Res. 62:2002;2993-2998